Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13% in November according to data from S&P Global Market Intelligence.
Here's a review of the key announcements made during the month:
Given the news, it isn't hard to figure out why investors had yet another profitable month.
Source: Fool.com
Alnylam Pharmace. Stock
€208.20
0.140%
The stock is an absolute favorite of our community with 51 Buy predictions and no Sell predictions.
Based on the current price of 208.2 € the target price of 425 € shows a potential of 104.13% for Alnylam Pharmace. which would more than double the current price.
